Uroplakin II (MRQ-71) Rabbit Monoclonal Antibody
Specialties: Genitourinary (GU) Pathology
The asymmetric-unit membrane plaques of the urothelium maintain the blood-urine barrier and prevent cells from rupturing during bladder distention. The molecular constituents of those plaques comprise four transmembrane uroplakin isoforms: uroplakin Ia, uroplakin Ib, uroplakin II, and uroplakin III, which are specific differentiation products of the urothelial cells. Uroplakin expression has been demonstrated by immunohistochemistry using antibodies specifically recognizing these four proteins. Of them, uroplakin II and uroplakin III immunoreactivities are demonstrated in urothelium lining urinary tract mucosae, in a membranous pattern along the apical surface of umbrella cells, but not detected in other tissue types. Uroplakin II expression is absent or rarely detectable in carcinomas of the prostate, breast, ovary, lung, and kidney and in colon adenocarcinomas. As compared to uroplakin III, uroplakin II expression is retained more frequently in urothelial carcinoma, with the immunoreactivity often in a cytoplasmic/membranous pattern.1-6
- Moll R, et al. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995; 147(5):1383-1397.
- Hoang LL, et al. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder. Arch Pathol Lab Med. 2014; 138(7):943-949.
- Li W, et al. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014; 142(6):864-871.
- Smith SC, et al. Uroplakin II outperforms uroplakin III in diagnostically challenging settings. Histopathology. 2014; 65(1):132-138.
- Broede A, et al. Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder. J Clin Pathol. 2016; 69(4):307-312.
- Tian W, et al. Utility of uroplakin II expression as a marker of urothelial carcinoma. Hum Pathol. 2015; 46(1):58-64.
Specifications
- Reactivity: paraffin
- Control: Urothelial carcinoma (Cytoplasmic, Membranous); Bladder (Cytoplasmic, Membranous); Ureter (Cytoplasmic, Membranous)
- Dilution Range: 1:50-1:100 *
Package Inserts
IFU
- IVD Rev. 0.0 (CMC49139000)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 491R-94 |
| 0.5 mL concentrate | 491R-95 |
| 1.0 mL concentrate | 491R-96 |
| 1.0 mL predilute ready-to-use | 491R-97 |
| 7.0 mL predilute ready-to-use | 491R-98 |
For research use only (RUO) in Canada
| 0.1 mL concentrate (RUO) | 491R-94-RUO |
| 1.0 mL concentrate (RUO) | 491R-96-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 491R-97-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 491R-98-RUO |
For research use only (RUO) in the EU
| 0.1 mL concentrate (RUO) | 491R-94-RUO |
| 1.0 mL concentrate (RUO) | 491R-96-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 491R-97-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 491R-98-RUO |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 491R-94-RUO |
| 1.0 mL concentrate (RUO) | 491R-96-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 491R-97-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 491R-98-RUO |
To request information on this product in additional countries, please click the button below.